Table 1.

Summary of Enrollment of Black Men Onto CRPC Trials

Enrollment	Sipuleucel-T	Radium-223 Chloride	Enzalutamide (pre-chemo)	Enzalutamide (post-chemo)	Abiraterone (pre-chemo)	Abiraterone (post-chemo)	Cabazitaxel	All Patients With CRPC in RCTs	Expected Black Enrollment*
Total patients	512	809	1,717	1,199	1,195	1,088	755	7,275
Random assignment	2:1	2:1	1:1	2:1	2:1	1:1	1:1	—
Percent black	5.8	2.0	2.0	3.9	3.6	2.8	5.3	3.3	15.8
No. of black patients	30	16	34	47	43	30	40	240	1,149
No. of black patients receiving trial drug	23	11	21	31	29	15	20	150	673

Abbreviations: chemo, chemotherapy; CRPC, castration-resistant prostate cancer; NCI, National Cancer Institute; RCT, randomized controlled trial.

^*Based on (1) conservative NCI enrollment data that 66% of the available black population enrolls onto NCI clinical trials; (2) the US population is approximately 12% black; (3) there is a greater than two-fold increase in the incidence of lethal prostate cancer in black men.^1a,9